Literature DB >> 20336775

B2 attenuates polyglutamine-expanded androgen receptor toxicity in cell and fly models of spinal and bulbar muscular atrophy.

Isabella Palazzolo1, Natalia B Nedelsky, Caitlin E Askew, George G Harmison, Aleksey G Kasantsev, J Paul Taylor, Kenneth H Fischbeck, Maria Pennuto.   

Abstract

Expanded polyglutamine tracts cause neurodegeneration through a toxic gain-of-function mechanism. Generation of inclusions is a common feature of polyglutamine diseases and other protein misfolding disorders. Inclusion formation is likely to be a defensive response of the cell to the presence of unfolded protein. Recently, the compound B2 has been shown to increase inclusion formation and decrease toxicity of polyglutamine-expanded huntingtin in cultured cells. We explored the effect of B2 on spinal and bulbar muscular atrophy (SBMA). SBMA is caused by expansion of polyglutamine in the androgen receptor (AR) and is characterized by the loss of motor neurons in the brainstem and spinal cord. We found that B2 increases the deposition of mutant AR into nuclear inclusions, without altering the ligand-induced aggregation, expression, or subcellular distribution of the mutant protein. The effect of B2 on inclusions was associated with a decrease in AR transactivation function. We show that B2 reduces mutant AR toxicity in cell and fly models of SBMA, further supporting the idea that accumulation of polyglutamine-expanded protein into inclusions is protective. Our findings suggest B2 as a novel approach to therapy for SBMA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20336775      PMCID: PMC3881232          DOI: 10.1002/jnr.22389

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  46 in total

1.  Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor.

Authors:  A Brunet; A Bonni; M J Zigmond; M Z Lin; P Juo; L S Hu; M J Anderson; K C Arden; J Blenis; M E Greenberg
Journal:  Cell       Date:  1999-03-19       Impact factor: 41.582

2.  Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases.

Authors:  Ruth A Bodner; Tiago Fleming Outeiro; Stephen Altmann; Michele M Maxwell; Stephanie H Cho; Bradley T Hyman; Pamela J McLean; Anne B Young; David E Housman; Aleksey G Kazantsev
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

3.  Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice.

Authors:  C J Cummings; E Reinstein; Y Sun; B Antalffy; Y Jiang; A Ciechanover; H T Orr; A L Beaudet; H Y Zoghbi
Journal:  Neuron       Date:  1999-12       Impact factor: 17.173

4.  Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients.

Authors:  Hiroaki Adachi; Masahisa Katsuno; Makoto Minamiyama; Masahiro Waza; Chen Sang; Yuji Nakagomi; Yasushi Kobayashi; Fumiaki Tanaka; Manabu Doyu; Akira Inukai; Mari Yoshida; Yoshio Hashizume; Gen Sobue
Journal:  Brain       Date:  2005-01-19       Impact factor: 13.501

5.  Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions.

Authors:  Elizabeth J Slow; Rona K Graham; Alexander P Osmand; Rebecca S Devon; Ge Lu; Yu Deng; Jacqui Pearson; Kuljeet Vaid; Nagat Bissada; Ronald Wetzel; Blair R Leavitt; Michael R Hayden
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-02       Impact factor: 11.205

6.  Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy.

Authors:  M Li; S Miwa; Y Kobayashi; D E Merry; M Yamamoto; F Tanaka; M Doyu; Y Hashizume; K H Fischbeck; G Sobue
Journal:  Ann Neurol       Date:  1998-08       Impact factor: 10.422

7.  Dynamic association of proteasomal machinery with the centrosome.

Authors:  W C Wigley; R P Fabunmi; M G Lee; C R Marino; S Muallem; G N DeMartino; P J Thomas
Journal:  J Cell Biol       Date:  1999-05-03       Impact factor: 10.539

8.  Characterization and dynamics of aggresome formation by a cytosolic GFP-chimera.

Authors:  R García-Mata; Z Bebök; E J Sorscher; E S Sztul
Journal:  J Cell Biol       Date:  1999-09-20       Impact factor: 10.539

9.  Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy.

Authors:  Isabella Palazzolo; Conor Stack; Lingling Kong; Antonio Musaro; Hiroaki Adachi; Masahisa Katsuno; Gen Sobue; J Paul Taylor; Charlotte J Sumner; Kenneth H Fischbeck; Maria Pennuto
Journal:  Neuron       Date:  2009-08-13       Impact factor: 17.173

10.  Progressive disruption of cellular protein folding in models of polyglutamine diseases.

Authors:  Tali Gidalevitz; Anat Ben-Zvi; Kim H Ho; Heather R Brignull; Richard I Morimoto
Journal:  Science       Date:  2006-02-09       Impact factor: 63.714

View more
  15 in total

Review 1.  Developing treatment for spinal and bulbar muscular atrophy.

Authors:  Kenneth H Fischbeck
Journal:  Prog Neurobiol       Date:  2012-06-02       Impact factor: 11.685

Review 2.  Aggregation formation in the polyglutamine diseases: protection at a cost?

Authors:  Tiffany W Todd; Janghoo Lim
Journal:  Mol Cells       Date:  2013-06-19       Impact factor: 5.034

Review 3.  Exploring the Role of Posttranslational Modifications in Spinal and Bulbar Muscular Atrophy.

Authors:  Neha Gogia; Luhan Ni; Victor Olmos; Fatema Haidery; Kimberly Luttik; Janghoo Lim
Journal:  Front Mol Neurosci       Date:  2022-06-03       Impact factor: 6.261

Review 4.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

Review 5.  In Vitro and In Vivo Modeling of Spinal and Bulbar Muscular Atrophy.

Authors:  Maria Pennuto; Manuela Basso
Journal:  J Mol Neurosci       Date:  2015-11-27       Impact factor: 3.444

Review 6.  Current status of treatment of spinal and bulbar muscular atrophy.

Authors:  Fumiaki Tanaka; Masahisa Katsuno; Haruhiko Banno; Keisuke Suzuki; Hiroaki Adachi; Gen Sobue
Journal:  Neural Plast       Date:  2012-06-07       Impact factor: 3.599

7.  Protein arginine methyltransferase 1 and 8 interact with FUS to modify its sub-cellular distribution and toxicity in vitro and in vivo.

Authors:  Chiara Scaramuzzino; John Monaghan; Carmelo Milioto; Nicholas A Lanson; Astha Maltare; Tanya Aggarwal; Ian Casci; Frank O Fackelmayer; Maria Pennuto; Udai Bhan Pandey
Journal:  PLoS One       Date:  2013-04-19       Impact factor: 3.240

Review 8.  The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution.

Authors:  Nico P Dantuma; Laura C Bott
Journal:  Front Mol Neurosci       Date:  2014-07-31       Impact factor: 5.639

Review 9.  New routes to therapy for spinal and bulbar muscular atrophy.

Authors:  Anna Rocchi; Maria Pennuto
Journal:  J Mol Neurosci       Date:  2013-02-19       Impact factor: 3.444

10.  Mechanisms mediating spinal and bulbar muscular atrophy: investigations into polyglutamine-expanded androgen receptor function and dysfunction.

Authors:  Lenore K Beitel; Carlos Alvarado; Shaza Mokhtar; Miltiadis Paliouras; Mark Trifiro
Journal:  Front Neurol       Date:  2013-05-15       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.